Patent intelligence · WO
WO 2025221754
UPADACITINIB DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE L'ARTÉRITE À CELLULES GÉANTES
UPADACITINIB DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE L'ARTÉRITE À CELLULES GÉANTES
Patent details — WO 2025221754
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Oct 23, 2025
- Expiration
- Oct 18, 2045
- Applicant
- ABBVIE INC [US]
- CPC classes
- A61K 31/ 4985 A I, A61K/314985, A61P 9/ 00 A I, A61P/900
Quick answer
WO 2025221754 (UPADACITINIB DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE L'ARTÉRITE À CELLULES GÉANTES) is held by ABBVIE INC [US]. Status: granted. Granted Oct 23, 2025. Expires Oct 18, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ABBVIE INC [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 4985 A I, A61K/314985, A61P 9/ 00 A I, A61P/900
More from ABBVIE INC [US]
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 2025221754?
WO 2025221754 (UPADACITINIB DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE L'ARTÉRITE À CELLULES GÉANTES) is held by ABBVIE INC [US]. Status: granted. Granted Oct 23, 2025. Expires Oct 18, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2025221754?
ABBVIE INC [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does WO 2025221754 expire?
Our index shows an expiration date of Oct 18, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.